里程碑式的卡利基金启动逾 18 个月后，仅募集到 7085 美元存款，远低于每年 10 亿美元的目标。该基金请求从数字序列信息（DSI）获利的企业自愿捐款。
Cali Biodiversity Fund Struggles as Big Pharma Withholds Voluntary Contributions The landmark Cali Fund has collected only $7,085 in deposited funds against its $1 billion annual target more than 18 months after its launch. The fund requests voluntary contributions from companies profiting from digital sequence information (DSI) derived from nature.
在亚美尼亚埃里温举行的第十七届生物多样性大会（Cop17）上，保护人士批评大型制药公司“免费搭便车”利用生物多样性，指出 2025 年排名前 15 位的药企利润达 1610 亿美元，按指导方针本可贡献 7.56 亿美元。
At the Cop17 biodiversity summit in Yerevan, Armenia, conservationists criticized major pharmaceutical companies for free-riding on biodiversity, noting that the top 15 drugmakers generated $161 billion in profits in 2025 and could have contributed $756 million under the guidelines.
对此，包括国际制药制造商及协会联合会在内的行业代表辩称，该基金机制与现有法律重叠，且不当要求企业按营收比例缴款，而不论是否实际使用了自然界的遗传数据。
In response, industry representatives, including the International Federation of Pharmaceutical Manufacturers and Associations, argued the fund's mechanism overlaps with existing laws and improperly asks for revenue-based contributions regardless of whether nature's genetic data was used.